Home Study Webcast
1.25 Contact Hour(s)
Thursday, April 20, 2023
Saturday, April 20, 2024
ACPE Expiration Date
Monday, April 20, 2026
Challenge accepted. Our country has made numerous strides in advancing patient care, and more particularly conducting efforts to ensure that lives within the national opioid crisis are saved and/or improved. One of those positive strides involves the FDA approval of abuse-deterrent formulation (ADF) opioid medications, with the aim of preventing the transition from the misuse and/or abuse of prescription opioid medications to illicit (and possibly laced) diacetylmorphine (a.k.a. heroin). How do these formulations work one might ask? What abuse-deterrent formulation (ADF) opioid medications are not only available on the U.S. market, but also specifically approved as an ADF opioid medication? Are these abuse-deterrent formulations really fool-proof? Well the street chemists of our country have already accepted the challenge to be knowledgeable on all of the above, now it’s our turn as healthcare professionals to get up to speed on these risk reduction entities. So please join us for this discussion as part of the overall Substances of Abuse Specialty Pharmacist (SASP) certificate training program.
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.
In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.
PharmD, MBA, BCGP, CPE, CTTS
Assistant Professor, West Virginia University School of Pharmacy
This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).